Population-scale analysis of common and rare genetic variation associated with hearing loss in adults - Praveen, Kavita; Dobbyn, Lee; Gurski, Lauren; Ayer, Ariane H.; Staples, Jeffrey; Mishra, Shawn; Bai, Yu; Kaufman, Alexandra; Moscati, Arden; Benner, Christian; Chen, Esteban; Chen, Siying; et al. (medRxiv, 2021)
Understanding the genetic underpinnings of disabling hearing loss, which affects ∼466 million people worldwide, can provide avenues for new therapeutic target development. We performed a genome-wide association meta-analysis of hearing loss with 125,749 cases and 469,497 controls across five cohorts, including UK Biobank, Geisinger DiscovEHR, the Malmö Diet and Cancer Study, Mount Sinai’s BioMe Personalized Medicine Cohort, and FinnGen. We identified 53 loci affecting hearing loss risk, 15 of which are novel, including common coding variants in COL9A3 and TMPRSS3. Through exome-sequencing of 108,415 cases and 329,581 controls from the same cohorts, we identified hearing loss associations with burden of rare coding variants in FSCN2 (odds ratio [OR] = 1.14, P = 1.9 × 10−15) and burden of predicted loss-of-function variants in KLHDC7B (OR = 2.14, P = 5.2 × 10−30). We also observed single-variant and gene-burden associations with 11 genes known to cause Mendelian forms of hearing loss, including an increased risk in heterozygous carriers of mutations in the autosomal recessive hearing loss genes GJB2 (Gly12fs; OR = 1.21, P = 4.2 × 10−11) and SLC26A5 (gene burden; OR = 1.96, P = 2.8 × 10−17). Our results suggest that loss of KLHDC7B function increases risk for hearing loss, and show that Mendelian hearing loss genes contribute to the burden of hearing loss in the adult population, suggesting a shared etiology between common and rare forms of hearing loss. This work illustrates the potential of large-scale exome sequencing to elucidate the genetic architecture of common traits in which risk is modulated by both common and rare variation.Competing Interest StatementRegeneron authors receive salary from and own options and/or stock of the company. Decibel authors receive salary and may own options and/or stock of the company.Funding StatementThis research received funding from Regeneron Pharmaceuticals. The exome sequencing was funded by the UK Biobank Exome Sequencing Consortium (i.e., Bristol Myers Squibb, Regeneron, Biogen, Takeda, Abbvie, Alnylam, AstraZeneca and Pfizer). This research has been conducted using the UK Biobank Resource under application number 2604.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided informed consent, and studies were approved by the individual IRBs at the respective institutions. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC), which covers the UK. It also sought the approval in England and Wales from the Patient Information Advisory Group (PIAG) for gaining access to information that would allow it to invite people to participate. The DiscovEHR study was approved by the IRB at Geisinger. The BioMe Biobank is an ongoing research biorepository approved by the Icahn School of Medicine at Mount Sinai IRB. The Ethical Committee at Lund University approved the Malmö Diet and Cancer Study (LU 51-90) and all the participants provided a written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll whole-exome sequencing, genotyping chip, and imputed sequence for UKB described in this report are publicly available to registered researchers via the UK Biobank data access protocol. Additional information about registration for access to the data is available at http://www.ukbiobank.ac.uk/register-apply/. Further information about the whole exome sequence is available at http://www.ukbiobank.ac.uk/wp-content/uploads/2019/03/Access_064-UK-Biobank-50k-Exome-Release-FAQ-v3.pdf Detailed information about the chip and imputed sequence is available at: http://www.ukbiobank.ac.uk/wp-content/uploads/2018/03/UKB-Genotyping-and-Imputation-Data-Release-FAQ-v3-2-1.pdf. Geisinger DiscovEHR, Malmo Diet and Cancer study and Mt. Sinai Biome exome sequencing and genotyping data can be made available to qualified, academic, non-commercial researchers upon request via a Data Transfer Agreement with the respective institutions. Summary statistics for FinnGen r3 can be downloaded from https://www.finngen.fi/en/access_results.